详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

A real-world disproportionality analysis of cidofovir from the FDA Adverse Event Reporting System (FAERS) database

4| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China [2]Harbin Med Univ, Affiliated Hosp 2, Dept Gen Surg, Harbin, Heilongjiang, Peoples R China

出处：

DOI：

ISSN：

关键词： FAERS human cytomegalovirus cidofovir adverse event pharmacovigilance signal mining

摘要：

BackgroundCidofovir, an antiviral drug used to treat cytomegalovirus retinitis in AIDS patients. While effective against several viruses, cidofovir's nephrotoxicity and other adverse events (AEs) limit its broader use. This study aims to evaluate the AE profile of cidofovir using data from the FAERS database.Research design and methodsAn analysis of FAERS data from the first quarter of 2004 to the fourth quarter of 2023 was performed. Signal detection was conducted using four algorithms: ROR, PRR, BCPNN, and EBGM. Data were categorized by system organ classes (SOCs) and preferred terms (PTs), and the strength of association between cidofovir and AEs was assessed.Results1,874 AE reports involving 1,266 patients were identified. 'Renal and urinary disorders,' 'Infections and infestations,' and 'Immune system disorders' were the most frequently reported SOCs, with the highest signal detected for 'Renal and urinary disorders.' Off-label use was the most common PT, highlighting the importance of controlling the indication of medication in clinical practice.ConclusionThis study identified significant signals related to cidofovir, suggesting that clinicians should carefully monitor patients, especially when using cidofovir for off-label purposes to mitigate potential risk outcomes. Further research is needed to optimize the safe and effective use of cidofovir.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版中科院分区表Review为是的期刊

：

大类 | 3 区医学

小类 | 3 区药学

最新[2025]版

：

大类 | 3 区医学

小类 | 3 区药学

JCR分区：

出版当年[2023]版：

Q2 PHARMACOLOGY & PHARMACY

最新[2024]版：

Q2 PHARMACOLOGY & PHARMACY

影响因子： 3.1 最新[2024版] 3.1 最新五年平均 3 出版当年[2023版] 3.6 出版当年五年平均 3.1 出版前一年[2022版] 3.1 出版后一年[2024版]

第一作者：

第一作者机构： [1]Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study [2]A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS) [3]Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS) [4]A pharmacovigilance study on the safety of faricimab in real-world scenario using FDA adverse event reporting system database [5]Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis [6]基于美国FDA不良事件报告系统数据库的英克司兰不良事件风险信号挖掘 [7]An observational study on the safety of teprotumumab based on FAERS database [8]Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database [9]Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years [10]Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER